Allergy Therapeutics plc Release: Appointment Of Dr Daphne Tsitoura As Head Of Clinical Science

Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces the appointment of Dr Daphne Tsitoura as Head of Clinical Science leading the Clinical Development team in Munich and Worthing from the 10th November, reporting to Professor Tim Higgenbottam.

Dr Tsitoura joins Allergy Therapeutics from GSK, where she has spent the last eight years as Principal Physician in the Respiratory Therapeutic Area in the GSKs' Stevenage Research Centre UK and has maintained a clinical link with allergy as an associate Allergist at University College Hospital London UK.

Previously she has held roles of Principal Immunologist at the Institute of Biomedical Research Academy of Athens, Consultant Physician / Chief of the Allergy Unit at the Henry Dunant Hospital Athens, senior fellow in immunology and allergy at Stanford University School of Medicine Palo Alto USA, and associate professor in Respiratory Medicine College of Physicians and Surgeons Columbia University New York.

Tim Higenbottam, R & D Director said:

"With an impressive career in medicine development and allergy, Daphne brings to Allergy Therapeutics a passion and drive to enhance the ease of use of allergy vaccines. She has a great depth of understanding of the therapeutic methods of modulation of the innate immune system to optimise allergy therapies. Her expertise will lend enormous support and strengthen our team of pharmaceutical experts and drive the research to gain approval of our Pollinex Quattro ultra-short course allergy vaccines in Europe and US."

-Ends-

For further information

Allergy Therapeutics +44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
www.allergytherapeutics.com

Peel Hunt LLP +44 (0) 20 7418 8900
James Steel / Clare Terlouw

FTI Consulting +44 (0) 20 3727 1000
Simon Conway / Victoria Foster Mitchell / Mo Noonan

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business with revenue of £42million achieved mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. 

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.